Source:http://linkedlifedata.com/resource/pubmed/id/19889012
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2010-2-3
|
pubmed:abstractText |
T-cell leukemia/lymphoma protein 1 (TCL1) was recently shown to display an expression pattern in chronic lymphocytic leukemia (CLL) corresponding to molecular subtypes, where poor-risk patients demonstrated higher expression levels. Here, we examined the mRNA expression pattern of TCL1 in 144 patients with CLL, including 67 immunoglobulin heavy-chain variable (IGHV) mutated, 58 IGHV unmutated and 19 patients with IGHV3-21 usage. A higher TCL1 expression level was detected in patients with CLL with unmutated vs. mutated IGHV genes (P < 0.001), whereas no difference was demonstrated within the IGHV3-21 cohort (i.e., mutated vs. unmutated and stereotyped vs. non-stereotyped complementarity determining region 3). The IGHV3-21 subgroup displayed high TCL1 mRNA expression, differing significantly from other IGHV mutated cases (P < 0.001), although 11/19 had mutated IGHV genes. Furthermore, high TCL1 expression levels were associated with significantly shorter overall survival (P < 0.001). Altogether, we show that TCL1 mRNA expression may predict clinical outcome in CLL and that the IGHV3-21 subset, regardless of mutational status, displays high TCL1 expression.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Heavy Chains,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Variable Region,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/TCL1A protein, human
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1600-0609
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
84
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
109-16
|
pubmed:meshHeading |
pubmed-meshheading:19889012-Adult,
pubmed-meshheading:19889012-Aged,
pubmed-meshheading:19889012-Aged, 80 and over,
pubmed-meshheading:19889012-Disease-Free Survival,
pubmed-meshheading:19889012-Female,
pubmed-meshheading:19889012-Gene Expression Regulation, Leukemic,
pubmed-meshheading:19889012-Humans,
pubmed-meshheading:19889012-Immunoglobulin Heavy Chains,
pubmed-meshheading:19889012-Immunoglobulin Variable Region,
pubmed-meshheading:19889012-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:19889012-Male,
pubmed-meshheading:19889012-Middle Aged,
pubmed-meshheading:19889012-Mutation,
pubmed-meshheading:19889012-Proto-Oncogene Proteins,
pubmed-meshheading:19889012-RNA, Messenger,
pubmed-meshheading:19889012-Risk Factors,
pubmed-meshheading:19889012-Survival Rate
|
pubmed:year |
2010
|
pubmed:articleTitle |
IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
|
pubmed:affiliation |
Dept of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden. mahmoud.mansouri@genpat.uu.se
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|